Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 50Colorectal Neoplasms 39Stomach Neoplasms 27Carcinoma, Hepatocellular 26Ovarian Neoplasms 25Melanoma 21Breast Neoplasms 20Carcinoma, Non-Small-Cell Lung 19Neoplasms 15Neoplasm Metastasis 15Colonic Neoplasms 14Esophageal Neoplasms 13Uterine Cervical Neoplasms 11Sarcoma 10Liver Neoplasms 10Carcinoma, Renal Cell 10Lung Neoplasms 9Anus Neoplasms 9Rectal Neoplasms 8Head and Neck Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Osteosarcoma 7Triple Negative Breast Neoplasms 6Mesothelioma 6Hepatoblastoma 6Gastrointestinal Neoplasms 6Carcinoma 6Adenocarcinoma 6Vaginal Neoplasms 5Small Cell Lung Carcinoma 5

Interventions

fludarabine phosphate 1fludarabine 1entinostat 1aldesleukin 1Thalidomide 1Radiotherapy, Image-Guided 1Psychiatric Rehabilitation 1Fentanyl 1Docetaxel 1Cyclophosphamide 1Bariatric Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × Cyclophosphamide × Gastrointestinal × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡